Hematology/Oncology

Top Story

Debate, fluidity continues over repeal, replacement of ACA

July 27, 2017

The United States Senate is more than halfway through 20 hours of debate over the so-called “skinny repeal” bill that would start the process of eliminating the Affordable Care Act.

Though the bill is very fluid and mostly unknown at the time of this writing, certain components have risen for discussion.

In the Journals

Renal transplant recipients at greater risk for melanoma

July 27, 2017
Renal transplant recipients had a greater risk than the general population for melanoma, according to recently published study results in JAMA Dermatology. Researchers…
Meeting News

Guest Commentary: Debu Tripathy, MD, reviews highlights in breast cancer from ASCO 2017

July 27, 2017
In this guest commentary, Debu Tripathy, MD, professor and chair of the department of breast medical oncology at The University of Texas MD Anderson Cancer Center and a

AstraZeneca, Merck to collaborate on olaparib development

July 27, 2017
AstraZeneca and Merck entered a global strategic collaboration to develop and commercialize olaparib to treat multiple malignancies. Olaparib (Lynparza, AstraZeneca)…
In the Journals

Women less likely to undergo immediate breast reconstruction at safety net hospitals

July 27, 2017
Women undergoing mastectomies at safety net hospitals were significantly less likely to undergo immediate breast reconstruction than women at non-safety net hospitals…
More Headlines »
CME

Combination Strategies in Melanoma Management: What’s New and What’s Next

This activity is supported by an educational grant from Genentech, Inc.

Melanoma is the sixth most common cancer in the United States and the deadliest form of skin cancer. Although it is…
More »
Video
Meeting News

VIDEO: Genomic risk system may help treat prostate cancer

July 19, 2017
More »
Resource Centers
Biosimilars in the US

Biosimilars in the US

CME

Hot Topics in Metastatic Breast Cancer Management: Clinical Advances with CDK4/6 Inhibitors

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

While the mortality rates for advanced or metastatic breast cancer (MBC) have steadily decreased, in part due to…
More »
Current Issues
View the Current Issue
HemOnc Today
Advertisement
Advertisement